All Articles

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.

This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.

In this inaugural video, the panel provides peer-to-peer perspectives on educating the care team and patients on the new classification of HER2-low mBC.

In this second installment, our expert panel suggests approaches to empowering patients to become involved in shared decision-making.

In the third video of this series, knowledgeable advance practice providers contribute their viewpoints on the attributes of targeted antibody drug conjugate therapy for mBC that may help some patients fulfill their treatment goals.

This video is the fourth in the series where skilled discussants share their approaches to managing patient expectations of treatment and side effects associated with antibody drug conjugate therapy for mBC.

The fifth video includes some suggested mBC resources and tools the panel utilizes to educate themselves, their colleagues, and patients.

To conclude this series, our seasoned panel describes how clinical trial and practical experiences with antibody drug conjugate therapy for mBC instill their confidence in this therapy.